Cowen analyst Joseph Thome reiterated an Outperform rating on Marinus Pharmaceuticals (NASDAQ: MRNS), following approval of the company's drug ganaxolone ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE